Last week in Barcelona, Precigen commercial leaders Phil Tennant and Joe Merkert joined over 130 companies and solution providers at the World Orphan Drug Congress Europe. Covering cell and gene therapy, genetic testing, market access, orphan drugs policies and real-world evidence, the congress is the largest of its kind across the globe and had a particular focus on a new Joint Clinical Assessment process for Europe coming into effect in January 2025. Precigen aims to stay at the forefront of these developments as it strives to deliver on its global commercialization ambition. Learn more about Precigen: www.precigen.com. #CellTherapy #GeneTherapy #Biopharma #OrphanDrug #RareDisease
Precigen
Biotechnology Research
Germantown, Maryland 5,339 followers
Precigen (Nasdaq: PGEN) is a biopharmaceutical company advancing the next generation of gene and cell therapies.
About us
Precigen: Advancing Medicine with Precision™ Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated unique therapies toward clinical proof-of-concept and commercialization.
- Website
-
http://www.precigen.com
External link for Precigen
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Germantown, Maryland
- Type
- Public Company
- Specialties
- Gene Therapy and Cell Therapy
Locations
-
Primary
20358 Seneca Meadows Pkwy
Germantown, Maryland 20876, US
Employees at Precigen
Updates
-
Thank you to everyone who came by Precigen's booth to meet our team members — Phil Tennant, Amy Lankford, and Joe Merkert — at the AAO-HNSF annual meeting in Miami these past few days. Understanding the latest data and trends in the otolaryngology field is critical as we seek to deliver on our mission of advancing therapeutic options in urgent and intractable diseases. A special thank you to Dr. Clint T. Allen from the National Cancer Institute for presenting important data for the #RecurrentRespiratoryPapillomatosis community. #OTOMTG24
-
Join us on Wednesday, September 18 for a fireside chat with Precigen's President and CEO, Helen Sabzevari, at the 2024 Cantor Global Healthcare Conference. View details and register for the webcast: https://bit.ly/3LqNK9i #CantorHCC
-
Precigen reports second quarter / first half 2024 financial results and business updates. View press release and join our conference call today at 4:30pm ET: https://bit.ly/3yGJAae
-
Join Precigen on Wednesday, August 14, 2024 at 4:30 PM ET for a conference call to discuss second quarter and first half 2024 financial results. View details: https://bit.ly/3LqNK9i
-
#ICYMI: Watch the replay of the webcast from #RRPAwarenessDay held on June 11, 2024 at the National Press Club in Washington, DC. We are so thankful to the patient and caregiver panelists for sharing their stories and bringing insights and hope to others, to National Cancer Institute (NCI) panelists for their dedication and tenacity in finding new treatment options for RRP patients, to Senator Mark Warner of Virginia for fighting for the rare disease community, and for Gov. Wes Moore of Maryland for supporting the RRP community and sharing his own family's experience with rare disease. A special thank you to our co-hosts at the RECURRENT RESPIRATORY PAPILLOMATOSIS FOUNDATION for everything you do for the RRP community, including co-creating this special awareness day and the associated event. We look forward to continuing our collaboration and #GivingVoicetoInspireChange for the RRP community. Watch the replay and checkout photos from the event at https://rrpawareness.org
-
We are incredibly grateful and inspired by the turnout for our inaugural #RRPAwarenessDay. People with RRP, caregivers, clinicians, researchers and industry innovators shared their inspiring stories and messages with the rare disease community. To the hundreds who participated at the National Press Club and via webcast, thank you! Together, we are shaping a hopeful and positive future for those impacted by RRP. We would like to extend our deepest gratitude to the RECURRENT RESPIRATORY PAPILLOMATOSIS FOUNDATION for its dedication to building a community among those affected by this devastating disease. Watch the #RRPAwarenessDay co-hosts share their thoughts on what they hope we achieved for RRP patients today. #RRPAwareness #GivingVoicetoInspireChange